Olanzapine + olanzapine + risperidone
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
Trial Timeline
Feb 1, 2004 → Sep 1, 2007
NCT ID
NCT00287820About Olanzapine + olanzapine + risperidone
Olanzapine + olanzapine + risperidone is a approved stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00287820. Target conditions include Schizophrenia, Diabetes, Metabolic Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00287820 | Approved | Completed |
Competing Products
20 competing products in Schizophrenia